RE:RE:RE:FTC blockage of Amgen's US$28 BLN takeover of Horizonwestcoast - your observation is the essence of a "bolt-on" acquisition that Big Pharma companies are increasingly interested in conducting given today's M&A environment. Also the lack of an anti-competitive perspective in the review of such a transaction is further driving Big Pharma's motivation.
Furthermore, the succesful completion of Pfizer US$43 Billion acquisition of Seagen in now in question, particularly following today's FTC Amgen/Horizon decision that was preceeded by the FTC's April 2023 decision to have Illumina divest it's US$7.3 Billion of the cancer test developer Grail, as another example.
https://www.cnbc.com/2023/04/03/ftc-orders-illumina-to-divest-grail-acquisition.html